| Type 2 Diabetes Mellitus |
1 |
1 |
| SGLT2 Inhibitor |
0 |
0.72 |
| Clinical Research |
0 |
0.41 |
| Healthcare and Medical Technology |
0 |
0.33 |
| Blood |
0 |
0.31 |
| Renal Disease |
0 |
0.22 |
| Kidney |
0 |
0.21 |
| Acute Coronary Syndrome |
0 |
0.18 |
| Urinary Tract Infection |
0 |
0.18 |
| Type 1 Diabetes Mellitus |
0 |
0.17 |
| Fournier Gangrene |
0 |
0.15 |
| Hemoglobin A1c |
0 |
0.15 |
| Angina Pectoris |
0 |
0.14 |
| Skin and Soft Tissue Infection |
0 |
0.14 |
| Amputation |
0 |
0.1 |
| Diet |
0 |
0.1 |
| Exercise |
0 |
0.1 |
| Gangrene |
0 |
0.1 |
| Hemoglobin |
0 |
0.1 |
| Hospital |
0 |
0.1 |
| Hypoglycemia |
0 |
0.1 |
| Infarction |
0 |
0.1 |
| Limb |
0 |
0.1 |
| Massachusetts |
0 |
0.1 |
| Pyelonephritis |
0 |
0.1 |
| Translational Research |
0 |
0.1 |
| Unstable Angina |
0 |
0.1 |
| Cardiovascular Risk Management |
0 |
0.08 |
| Cerebrovascular Accident |
0 |
0.08 |
| Myocardial Infarction (MI) |
0 |
0.08 |